ENGN Stock Forecast & Price Target

enGene Therapeutics is supported by a credible path to commercialization because detalimogene is advancing toward BLA submission, with a pre-BLA meeting in 4Q26 and an updated pivotal readout also expected in 4Q26, which could de-risk the regulatory story. The fundamental bullish case rests on its differentiated profile in NMIBC: a non-viral, easy-to-administer therapy with reduced dwell time, strong tolerability, and 91% of TRAEs being Grade 1-2 and only 4.8% Grade 3, features that fit resource-constrained community practices where ease-of-use and workflow matter. Although durability is still immature after a 54% CR anytime rate and 25% 12-month CR at AUA 2026, management believes roughly $1B net sales could come from about 10% share or 2,000 patients at parity pricing, with payer coverage potentially aided by NCCN guideline inclusion.

enGene Therapeutics is facing a weaker fundamental case because the pivotal LEGEND Cohort 1 update fell short on 12-month durability, raising doubt that detalimogene can deliver consistent efficacy in high-risk BCG-unresponsive NMIBC. Management’s decision to cut workforce by approximately 50% and halt enrollment in Cohorts 2a, 2b, and 3 underscores both execution strain and the need to conserve capital, even with $285.2M in cash, cash equivalents, and marketable securities as of April 30, 2026. With only a 30% probability of success assigned, a reduced peak penetration assumption of 25%, and major uncertainty around FDA interpretation, NCCN inclusion, and future cash burn through BLA submission in 2H26, the risk-reward profile remains unattractive.